Image

Associate Professor Amee George leads a specific research program into disorders of ribosome biogenesis (ribosomopathies) and the molecular mechanism(s) and signalling pathways which link this process to the nucleolus, a key structure in ribosome biogenesis. She is also a national specialist in high-throughput and high-content screening, leading the ANU Centre for Therapeutic Discovery.

Closely collaborating with the Hannan Group, the George Group has a research interest in:

• identifying disease biomarkers (genotype-phenotype) and therapeutic targets for drug discovery,
• utilising functional (RNAi/CRISPR) and molecule/biologic approaches and high-content imaging readouts
• developing new approaches to model disease in vitro, with a view to use these models for drug discovery projects (including complex 2D and 3D cellular models).